Keynote-D18 might have failed on a technicality, but now cash is running out.

ALX2004 starts phase 1, along with the sixth oncology-focused in vivo Car-T.

A second global pivotal trial will test iza-bren in the same NSCLC setting where patri-dxd failed.

If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.

The speciality pharma will gain the approved Danyelza and a radiopharma pipeline.

A phase 2 trial of the Car-T project BNT211 is withdrawn just months after it began.

The move comes after a death in the Alpha-3 cema-cel study.

The company gets another odronextamab knockback, while a key fianlimab readout is postponed.

Approvals come for Regeneron and Dizal, but Roche and Replimune see knockbacks.

Jazz’s Chimerix buy faces its big test.